Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flumatinib
- Development stage
- Phase 4
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flumatinib is an orally bioavailable small molecule tyrosine kinase inhibitor developed for the treatment of Philadelphia chromosome-positive leukemias, particularly chronic myeloid leukemia (CML). It selectively inhibits wild-type and certain mutant forms of BCR-Abl fusion protein, platelet-derived growth factor receptor (PDGFR), and mast/stem cell growth factor receptor (c-Kit), thereby blocking their signal transduction pathways. This inhibition suppresses the proliferation and survival of tumor cells dependent on these kinases. Flumatinib has demonstrated higher efficacy and a lower rate of side effects compared to imatinib in clinical trials for CML, including activity against some resistant mutations. It is approved in China for newly diagnosed CML-chronic phase patients and has also shown potential activity in acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs) with certain KIT mutations[1][4][7][8].
- Brand names
- Flumatinib
- Other names
- Flumatinib mesylateFlumatinib free base
02
Targets
PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on Flumatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flumatinib.